WEBULL
WebtradeDownload

Why Becton Dickinson (BDX) Is Getting Attention Today

Simply Wall St · 3d ago

Becton Dickinson (BDX) is back in focus after fresh clinical data from its AGILITY trial showed positive nine month outcomes for the Revello Vascular Covered Stent in iliac artery disease, alongside a new multibillion dollar US manufacturing partnership.

Those fresh AGILITY data and the multibillion dollar US manufacturing deal land at a moment when Becton Dickinson’s recent momentum has been picking up. The share price has climbed 20.98% over the past 90 days and 5.35% over the last month. Even though the year-to-date share price return is still down 3.88%, the 1-year total shareholder return of 29.75% points to a stronger payoff for investors who stayed in through dividends and reinvestment.

See how Becton Dickinson compares with other high quality balance sheet plays and which stocks make the cut in our curated list of solid balance sheet and fundamentals (25 results)

Becton Dickinson has just logged a strong 90 day run and secured fresh clinical and manufacturing milestones, so the real question now is whether the current valuation still leaves enough upside to justify new risk.

Most Popular Narrative: 4% Undervalued

Against a last close of $187.37, the most widely followed narrative tags Becton Dickinson with a fair value of $195.67. This points to modest upside already sketched into expectations and places more weight on execution than on multiple expansion.

The BD Excellence operating system continues to drive roughly 8% plant productivity and is being extended into commercial, R&D and AI enabled supply chain. This is intended to sustain margin expansion, support the roughly 25% adjusted operating margin and contribute to free cash flow and earnings over time.

See why 27 investors see Becton Dickinson as 4% undervalued.

Result: Fair Value of $195.67 (UNDERVALUED)

Still, two weak spots could trip this Becton Dickinson narrative: persistent revenue pressure in China and a sharper slowdown as the Alaris replacement cycle fades.

Find out about the key risks to this Becton Dickinson narrative.

Next Steps

Mixed signals on Becton Dickinson’s story so far. If you want your own take, move quickly and weigh both the upside and the caution flags in the 4 key rewards and 2 important warning signs.

Looking for more Becton Dickinson sized ideas?

Do not stop with Becton Dickinson. Use fresh screener results to pressure test your thinking and line up the next few candidates on your watchlist.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.